News
A clash is brewing between doctors and patients when it comes to treatment for sleep apnea in those with obesity, a new study reports.
Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity.
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, marking the ...
The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...
But Zepbound is only for people with obesity and sleep apnea, the AASM noted. Also, Zepbound can reduce the severity of sleep apnea through weight loss but might not cure the problem.
Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...
Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...
Key Takeaways Patients and doctors are disagreeing about sleep apnea treatmentDoctors favor the use of CPAP machinesBut patients with obesity would rather use Zepbound to ease their apnea MONDAY ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results